WO1994021807B1 - Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin - Google Patents
Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccinInfo
- Publication number
- WO1994021807B1 WO1994021807B1 PCT/GB1994/000572 GB9400572W WO9421807B1 WO 1994021807 B1 WO1994021807 B1 WO 1994021807B1 GB 9400572 W GB9400572 W GB 9400572W WO 9421807 B1 WO9421807 B1 WO 9421807B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- mutant
- hsv
- gene
- use according
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract 45
- 230000001177 retroviral effect Effects 0.000 title claims abstract 10
- 230000002950 deficient Effects 0.000 title claims abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000700584 Simplexvirus Species 0.000 claims abstract 27
- 208000015181 infectious disease Diseases 0.000 claims abstract 17
- 230000002458 infectious effect Effects 0.000 claims abstract 15
- 238000004519 manufacturing process Methods 0.000 claims abstract 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 10
- 230000001225 therapeutic effect Effects 0.000 claims abstract 9
- 230000003612 virological effect Effects 0.000 claims abstract 9
- 102000003886 Glycoproteins Human genes 0.000 claims abstract 5
- 108090000288 Glycoproteins Proteins 0.000 claims abstract 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims abstract 5
- 230000007547 defect Effects 0.000 claims abstract 5
- 101150055782 gH gene Proteins 0.000 claims abstract 5
- 230000028993 immune response Effects 0.000 claims abstract 5
- 230000000069 prophylactic effect Effects 0.000 claims abstract 5
- 108091007433 antigens Proteins 0.000 claims abstract 4
- 230000010076 replication Effects 0.000 claims abstract 4
- 244000052769 pathogen Species 0.000 claims 7
- 230000001717 pathogenic effect Effects 0.000 claims 7
- 108700039887 Essential Genes Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 206010061978 Genital lesion Diseases 0.000 claims 3
- 230000001815 facial effect Effects 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 3
- 208000009889 Herpes Simplex Diseases 0.000 abstract 1
Abstract
L'invention concerne un produit pharmaceutique contenant un virus mutant non rétroviral (particulièrement HSV-1 et/ou HSV-2) dont le génome est défectueux par rapport à un gène essentiel à la production du virus infectieux. Le virus peut infecter des cellules normales et subir la réplication et l'expression de gènes antigéniques viraux dans lesdites cellules mais ne peut pas produire des virus infectieux normaux. Le produit pharmaceutique est conçu pour une utilisation prophylactique ou thérapeutique dans le but de déclencher une réaction immune chez un sujet infecté. Dans le cas où le virus non rétroviral serait un virus d'Herpès Simplex, par exemple, HSV-1 ou HSV-2, le défaut peut se trouver dans le gène gH de glycoprotéine. Les vaccins et les produits pharmaceutiques thérapeutiques sont particulièrement conçus pour être administrés par voie épithéliale, orale, vaginale ou nasale. L'invention concerne également l'utilisation d'un mutant à base de HSV-1 servant à la préparation d'un produit pharmaceutique à usage prophylactique ou thérapeutique dans le déclenchement d'une réaction immune chez un sujet infecté par HSV de type 2.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6520817A JPH08507784A (ja) | 1993-03-19 | 1994-03-21 | ウイルス・ワクチン |
| AU62617/94A AU696336B2 (en) | 1993-03-19 | 1994-03-21 | Defective mutant non-retroviral virus (e.g. HSV) as vaccine |
| EP94909990A EP0689603A1 (fr) | 1993-03-19 | 1994-03-21 | Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9305710.7 | 1993-03-19 | ||
| GB939305710A GB9305710D0 (en) | 1993-03-19 | 1993-03-19 | Viral vaccines |
| GB9324964.7 | 1993-12-06 | ||
| GB939324964A GB9324964D0 (en) | 1993-12-06 | 1993-12-06 | Viral vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1994021807A2 WO1994021807A2 (fr) | 1994-09-29 |
| WO1994021807A3 WO1994021807A3 (fr) | 1994-12-08 |
| WO1994021807B1 true WO1994021807B1 (fr) | 1994-12-22 |
Family
ID=26302619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1994/000572 WO1994021807A2 (fr) | 1993-03-19 | 1994-03-21 | Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0689603A1 (fr) |
| JP (1) | JPH08507784A (fr) |
| AU (1) | AU696336B2 (fr) |
| CA (1) | CA2158148A1 (fr) |
| WO (1) | WO1994021807A2 (fr) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
| US5807557A (en) * | 1994-07-25 | 1998-09-15 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex |
| US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
| GB9423663D0 (en) * | 1994-11-23 | 1995-01-11 | Cantab Pharma Res | Viral preparations, immunogens, and vaccines |
| ATE324435T1 (de) * | 1995-02-21 | 2006-05-15 | Cantab Pharmaceuticals Res Ltd | Virale zubereitungen, vektoren, immunogene und impfstoffe |
| CA2215162A1 (fr) * | 1995-03-23 | 1996-09-26 | Cantab Pharmaceuticals Research Limited | Vecteurs d'apport de genes |
| WO1996040726A1 (fr) | 1995-06-07 | 1996-12-19 | Genta Incorporated | Nouveaux lipides cationiques a base de carbamate |
| US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
| JPH11513565A (ja) * | 1995-10-19 | 1999-11-24 | セント ジュード チルドレンズ リサーチ ホスピタル | ヘルペスウィルスベクター及びその利用 |
| US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
| HUP0002922A3 (en) | 1997-04-28 | 2003-03-28 | Aventis Pharma Sa | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
| GB9721909D0 (en) * | 1997-10-17 | 1997-12-17 | Cantab Pharma Res | Gene delivery vectors and their uses |
| US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
| GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| GB9808922D0 (en) | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| US6225456B1 (en) | 1998-05-07 | 2001-05-01 | University Technololy Corporation | Ras suppressor SUR-5 |
| US6506889B1 (en) | 1998-05-19 | 2003-01-14 | University Technology Corporation | Ras suppressor SUR-8 and related compositions and methods |
| GB9816761D0 (en) | 1998-07-31 | 1998-09-30 | Phogen Limited | Herpesvirus preparations and their uses |
| US6399354B1 (en) | 1998-07-31 | 2002-06-04 | President And Fellows Of Harvard College | Replication-competent virus expressing a detectable fusion protein |
| US6441156B1 (en) * | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
| GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
| IL151348A0 (en) | 2000-04-13 | 2003-04-10 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| AU6197800A (en) | 2000-05-10 | 2001-11-20 | Mayo Foundation | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| US7179614B2 (en) | 2000-09-14 | 2007-02-20 | Mount Sinai School Of Medicine | Screening methods to identify compounds that modulate type I phosphodiesterase (PDE) activity |
| US7060442B2 (en) | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
| BR0116756A (pt) | 2000-12-28 | 2005-01-04 | Wyeth Corp | Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma |
| CN1610556A (zh) | 2001-03-02 | 2005-04-27 | 洛克菲勒大学 | 保留天然变应原的免疫原性并具减弱的变应原性的重组杂合变应原构建体 |
| US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| US7432057B2 (en) | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
| US7604798B2 (en) | 2004-07-15 | 2009-10-20 | Northwestern University | Methods and compositions for importing nucleic acids into cell nuclei |
| JP4772045B2 (ja) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン |
| GB2421025A (en) * | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
| US7439327B2 (en) | 2005-01-18 | 2008-10-21 | Nuvelo, Inc. | Stem cell factor-like proteins and uses thereof |
| CN101437539B (zh) | 2005-07-05 | 2013-10-02 | 康奈尔研究基金会（有限公司） | 通过干扰cd99l2阻断白细胞迁出和炎症 |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
| CN102123732A (zh) | 2008-06-20 | 2011-07-13 | 杜克大学 | 用于引发免疫应答的组合物，方法及试剂盒 |
| CN102316894A (zh) | 2008-06-20 | 2012-01-11 | 惠氏有限责任公司 | 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法 |
| MX2011004755A (es) | 2008-11-05 | 2011-10-10 | Wyeth Llc | Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs). |
| WO2010096561A1 (fr) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protéines gag du vih/vis de synthèse et leurs utilisations |
| EP2547368A4 (fr) | 2010-03-19 | 2014-08-06 | Univ South Alabama | Méthodes et compositions pour le traitement du cancer |
| MX350142B (es) | 2010-08-23 | 2017-08-28 | Wyeth Llc * | Formulaciones estables de antigenos rlp2086 de neisseria meningitidis. |
| EP3056212B1 (fr) | 2010-09-10 | 2019-04-03 | Wyeth LLC | Dérivés non-lipidés des antigènes orf2086 de neisseria meningitidis |
| US9458456B2 (en) | 2011-04-01 | 2016-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
| US9464291B2 (en) | 2012-01-06 | 2016-10-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| MX351993B (es) | 2012-03-09 | 2017-11-03 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| WO2014136064A2 (fr) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Polypeptides immunogènes de fusion |
| CA2940513C (fr) | 2013-03-11 | 2023-08-15 | University Of Florida Research Foundation, Inc. | Delivrance d'une proteine a domaine de recrutement des caspases (card) en tant que therapie pour inflammation oculaire |
| US9822150B2 (en) | 2013-09-08 | 2017-11-21 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3049092A4 (fr) | 2013-09-24 | 2017-09-06 | Duke University | Compositions, procédés et kits pour déclencher une réponse immunitaire |
| EP3107939B1 (fr) | 2014-02-19 | 2020-06-17 | University of Florida Research Foundation, Inc. | Administration de nrf2 en tant que thérapie de protection contre les dérivés réactifs de l'oxygène |
| US10918712B2 (en) | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
| CN106456805B (zh) * | 2014-03-03 | 2020-01-10 | 阿尔伯特爱因斯坦医学院公司 | 重组单纯疱疹病毒2(hsv-2)疫苗载体 |
| WO2016132294A1 (fr) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Compositions de neisseria meningitidis et méthodes associées |
| WO2018142280A2 (fr) | 2017-01-31 | 2018-08-09 | Pfizer Inc. | Compositions de neisseria meningitidis et méthodes associées |
| US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| CA3061678A1 (fr) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Composition contenant un virus stable |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0550553B1 (fr) * | 1990-09-25 | 2000-07-12 | Cantab Pharmaceuticals Research Limited | Vaccin viral mutant a genome deficient et produit en transcomplementant la lignee cellulaire |
| TW289731B (fr) * | 1992-07-09 | 1996-11-01 | Akzo Nv | |
| EP0606437B1 (fr) * | 1992-07-30 | 2005-02-02 | Akzo Nobel N.V. | Vaccin d'herpesvirus vivant non excretable |
-
1994
- 1994-03-21 JP JP6520817A patent/JPH08507784A/ja active Pending
- 1994-03-21 WO PCT/GB1994/000572 patent/WO1994021807A2/fr not_active Application Discontinuation
- 1994-03-21 CA CA002158148A patent/CA2158148A1/fr not_active Abandoned
- 1994-03-21 EP EP94909990A patent/EP0689603A1/fr not_active Withdrawn
- 1994-03-21 AU AU62617/94A patent/AU696336B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1994021807B1 (fr) | Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin | |
| US5928913A (en) | Vectors for gene delivery | |
| McLAUCHLAN et al. | Noninfectious L-particles supply functions which can facilitate infection by HSV-1 | |
| WO1994021807A3 (fr) | Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin | |
| AU711121B2 (en) | Viral preparations, vectors, immunogens, and vaccines | |
| JP3334876B2 (ja) | 組換え単純ヘルペスウイルスワクチン及び方法 | |
| Subak-Sharpe et al. | HSV molecular biology: general aspects of herpes simplex virus molecular biology | |
| Bonneau et al. | Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity | |
| Collard et al. | Cells transformed by human herpesvirus type 2 transcribe virus-specific RNA sequences shared by herpesvirus types 1 and 2 | |
| Dargan et al. | The effect of herpes simplex virus type 1 L-particles on virus entry, replication, and the infectivity of naked herpesvirus DNA | |
| JPH10503372A (ja) | Ｈｓｖウイルスベクター | |
| JP2004535798A (ja) | ヘルペスウイルスを用いた癌処置のための組成物および方法 | |
| US20170275339A1 (en) | Herpes simplex virus vaccine | |
| CN115927473B (zh) | 一种用于单纯疱疹病毒感染性疾病的基因治疗药物 | |
| Watanabe et al. | Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector | |
| EP1002055A1 (fr) | Recuperation de virus a partir d'une culture cellulaire au moyen d'une solution salee hypertonique | |
| Dudek et al. | Disruption of the UL41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes | |
| Lu et al. | High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection | |
| CN100378216C (zh) | gM-阴性EHV突变体 | |
| CN117295516A (zh) | 用于治疗hsv的疫苗组合物和方法 | |
| Brans et al. | Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1 | |
| Gompels et al. | Infectivity determinants encoded in a conserved gene block of human herpesvirus-6 | |
| Sarkadi | Varicella-zoster virus vaccine, successes and difficulties | |
| CN112481222B (zh) | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 | |
| Lin | The Epstein-Barr virus DNA polymerase transactivates the human immunodeficiency virus type 1 5′ long terminal repeat |